title: Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study': reply from authors.
authors.affiliation: St. John's Institute of Dermatology, Guys and St Thomas' NHS Foundation Trust, London, SE1 9RT, U.K. satveer.mahil@gmail.com.
authors.forename: S K
authors.initials: SK
authors.lastname: Mahil
authors.forename: C H
authors.initials: CH
authors.lastname: Smith
mesh_terms: D000893:Anti-Inflammatory Agents / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor